Abstract
Understanding how gene-environment interactions (GEIs) influence the circulating proteome could aid in biomarker discovery and validation. The presence of GEIs can be inferred from single nucleotide polymorphisms that associate with phenotypic variability - termed variance quantitative trait loci (vQTLs). Here, vQTL association studies are performed on plasma levels of 1,468 proteins in 53,752 UK Biobank participants. A set of 683 independent vQTLs are identified across 571 proteins, all of which are newly discovered. They include 65 variants that lack conventional additive main effects on protein levels. Over 1,400 GEIs are identified between 142 proteins and 101 lifestyle and metabolic exposures. GEI analyses uncover biological mechanisms that explain why 13/65 vQTL-only sites lack corresponding main effects. Stratified analyses also highlight how age, sex and genotype can interact to modify relationships between biomarkers and health-related traits. This study establishes the most comprehensive database yet of vQTLs and GEIs for the human proteome.
Competing Interest Statement
T.L., K.F., H.M., H.R. and B.B.S are employed by Biogen. T.M., Z.K. and C.N.F. are employed by Optima Partners. R.F.H., D.A.G. and R.E.M. act as scientific consultants for Optima Partners. R.E.M. is an advisor to the Epigenetic Clock Development Foundation and has received speaker fees from Illumina. R.F.H. has received consultant fees from Illumina. All other authors declare no competing interests.
Funding Statement
This research was funded in whole, or in part, by the Wellcome Trust [108890/Z/15/Z]. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. We thank the participants, contributors, and researchers of UK Biobank for making data available for this study with special thanks to Lauren Carson, John Busby, Naomi Allen and Rory Collins for making the study possible. We are grateful to the research and development leadership teams at the thirteen participating UKB-PPP member companies (Alnylam Pharmaceuticals, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Calico, Genentech, Glaxo Smith Klein, Janssen Pharmaceuticals, Novo Nordisk, Pfizer, Regeneron, and Takeda) for funding the study. We thank the Legal and Business Development teams at each company for overseeing the contracting of this complex, precompetitive collaboration with particular thanks to Erica Olson of Amgen, Andrew Walsh of GSK and Fiona Middleton of AstraZeneca. Finally, we thank the team at Olink Proteomics (Philippa Pettingell, Klev Diamanti, Cindy Lawley, Linda Jung, Sara Ghalib, Ida Grundberg and Jon Heimer) for their consistent logistic support throughout the project with special thanks to Evan Mills for cochampioning the project and leading internal activities at Olink. R.E.M. is supported by Alzheimers Research UK major project grant ARUKPG2017B10 and Alzheimers Society major project grant ASPG19b010. D.A.G. is supported by the Wellcome Trust Translational Neuroscience programme [108890/Z/15/Z]. R.F.H is supported by a British Heart Foundation Immediate Fellowship [FS/IPBSRF/22/27042].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided informed consent. This research has been conducted using the UK Biobank Resource under approved application numbers 65851, 20361, 26041, 44257, 53639, 69804.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Genome-wide vQTL summary statistics and GEI association data will be made available via an open-access repository upon publication. Proteomics data are available in UK Biobank under return dataset [return dataset ID and URL will be provided upon publication].
